Willamette Valley Cancer Institute

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Cervical cancer2 trials
• Endometrial cancer2 trials
• Mantle cell lymphoma2 trials
• Ovarian cancer2 trials
• Prostate cancer2 trials
• Triple-negative breast cancer2 trials
• Acute myeloid leukaemia1 trial
• Bladder cancer1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Follicular lymphoma1 trial
• Gastric and oesophageal cancer1 trial
• and 5 more

Phase

• Phase 24 trials
• Phase 33 trials
• Phase 2/32 trials
• Phase 11 trial

Status

• Recruiting5 trials
• Completed3 trials
• Terminated2 trials

Lead sponsor

• Bristol-Myers Squibb2 trials
• Incyte Corporation2 trials
• Agenus Inc.1 trial
• Celgene1 trial
• Immuneering Corporation1 trial
• and 3 more

Running trials

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

  Contact: Jeanne Schaffer

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Miho Dougherty, Site 0316

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Verastem, Inc.· Source

  Contact: Jeanne Scahffer

• Recruiting

  Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  NCT03435796· Phase 2/3· Celgene· Source

  Contact: Jeff Sharman, Site 01052

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT05169684· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

  NCT04463771· Phase 2· Incyte Corporation· Source

• Terminated

  RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

  NCT03894215· Phase 2· Agenus Inc.· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source

• Completed

  Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

  NCT02635672· Phase 1· Vincerx Pharma, Inc.· Source